Here, we demonstrate that a triple combination of the AKTi, CDK4/6i, and fulvestrant is required to durably impair growth and prevent progression in ER+ breast cancer cell lines and tumor xenografts resistant to combined therapy with fulvestrant and CDK4/6i or fulvestrant alone. Here, ESR1 is linked to breast cancer.